Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Sickle Cell Disease Treatment Market’s Growth Trajectory From 2025 To 2034?
The market size for treating sickle cell disease has seen a swift expansion in the recent past. The growth is projected to shoot up from $2.95 billion in 2024 to $3.51 billion in 2025, with a compound annual growth rate (CAGR) set at 18.7%. The surge during the historic period can be credited to factors like comprehension of the disease, blood transfusion procedures, pain control measures, and the application of hydroxyurea therapy.
The market for treatment of sickle cell disease is anticipated to witness a swift expansion in the upcoming years, potentially reaching a valuation of$6.72 billion by 2029, growing at a compound annual growth rate (CAGR) of 17.7%. The predicted growth over this period could be due to factors such as advancements in gene editing and therapy, development of new drugs, introduction of telemedicine and remote monitoring, along with worldwide health initiatives. Major trends projected for this period encompass curative therapies, alternative methods for pain management, international collaborations, and heightened patient advocacy and engagement.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp
What External and Internal Drivers Are Contributing to the Growth of theSickle Cell Disease Treatment Market?
The surge in the need for blood transfusions is anticipated to accelerate the growth of the sickle cell disease treatment market. Blood transfusions, a medical procedure where blood or blood products are transferred from one person (the donor) to another (the recipient), play a pivotal role in the treatment of sickle cell disease (SCD). They enhance the blood’s capability to transport oxygen and reduce the complications related to vaso-occlusion. For example, in January 2022, Mid-Atlantic Long-Term Care, a US-based organization offering specialized 24-hour triage on-call service, reported that approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6.500 units of plasma are required daily in the US. Hence, the growing need for blood transfusions is fostering the expansion of the sickle cell disease treatment market.
What Segment Types Define the Sickle Cell Disease Treatment Market Structure?
The sickle cell disease treatmentmarket covered in this report is segmented –
1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion; Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea; L-Glutamine; Voxelotor; Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant; Autologous Transplant
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13048&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Sickle Cell Disease Treatment Market?
North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Sickle Cell Disease Treatment Market?
Firms dominating the market for sickle cell disease treatment are concentrating on creating new oral suspension drugs in a bid to elevate patient adherence, escalate drug effectiveness, and offer easier treatment options. This is particularly beneficial for pediatric and elderly patients. Oral suspension drugs are medications offered in liquid form with solid particles, engineered to simplify swallowing, especially for children or those who find it challenging to consume pills. An illustration of this is when Akums Drugs and Pharmaceuticals Ltd., a pharmaceutical production company based in India, introduced a non-refrigerated oral suspension of Hydroxyurea in March 2024. This SCD medication, priced at less than 1% of imported alternatives, eliminates cold storage requirements while providing accurate far-reaching dosing accessible to patients of all ages. It was aimed to boost healthcare access in India.
View the full report here:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
What Is the Definition of the Sickle Cell Disease Treatment Market?
Sickle cell disease (SCD), also known as sickle cell anemia, is a genetic disorder affecting hemoglobin, a protein in red blood cells. A mutation in the hemoglobin gene causes the production of defective hemoglobin, referred to as hemoglobin S (HbS), in people with sickle cell disease. The sickle cell disease treatment removes blockages, enhances blood flow and repairs damaged tissues.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13048
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model